Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cara Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for chronic pruritus. Its lead product, difelikefalin, is approved for treating pruritus associated with advanced chronic kidney disease in multiple countries. The company engages in licensing, collaboration, and royalty arrangements, with a business model centered on drug development, strategic partnerships, and out-licensing to maximize global reach and shareholder value.
This description was generated via AI from an annual report. Updated about 1 year ago.